Cancer continues to pose a significant global health challenge. While platinum-based chemotherapeutics, such as oxaliplatin, have been foundational—notably for their ability to induce immunogenic cell death (ICD)—their utility is often limited by severe side effects and acquired resistance. This has driven the search for innovative alternatives "beyond platinum." Non-platinum transition metal complexes, including those of ruthenium, iridium, and gold, have emerged as highly promising candidates. These agents offer distinct chemical properties, favorable toxicity profiles, and novel mechanisms of action, such as mitochondrial targeting, utility in photodynamic therapy, and the ability to circumvent drug resistance pathways. This Special Issue aims to highlight the latest advances in the design, synthesis, and therapeutic application of these next-generation metal-based anticancer agents, showcasing their potential to enable more precise, effective, and safer cancer therapies.